Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Molecules ; 27(1)2021 Dec 29.
Article in English | MEDLINE | ID: mdl-35011432

ABSTRACT

The rising tide of antibacterial drug resistance has given rise to the virtual elimination of numerous erstwhile antibiotics, intensifying the urgent demand for novel agents. A number of drugs have been found to possess potent antimicrobial action during the past several years and have the potential to supplement or even replace the antibiotics. Many of these 'non-antibiotics', as they are referred to, belong to the widely used class of neuroleptics, the phenothiazines. Another chemically and pharmacologically related class is the thioxanthenes, differing in that the aromatic N of the central phenothiazine ring has been replaced by a C atom. Such "carbon-analogues" were primarily synthesized with the hope that these would be devoid of some of the toxic effects of phenothiazines. Intensive studies on syntheses, as well as chemical and pharmacological properties of thioxanthenes, were initiated in the late 1950s. Although a rather close parallelism with respect to structure activity relationships could be observed between phenothiazines and thioxanthenes; several thioxanthenes were synthesized in pharmaceutical industries and applied for human use as neuroleptics. Antibacterial activities of thioxanthenes came to be recognized in the early 1980s in Europe. During the following years, many of these drugs were found not only to be antibacterial agents but also to possess anti-mycobacterial, antiviral (including anti-HIV and anti-SARS-CoV-2) and anti-parasitic properties. Thus, this group of drugs, which has an inhibitory effect on the growth of a wide variety of microorganisms, needs to be explored for syntheses of novel antimicrobial agents. The purpose of this review is to summarize the neuroleptic and antimicrobial properties of this exciting group of bioactive molecules with a goal of identifying potential structures worthy of future exploration.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antipsychotic Agents/pharmacology , Bacteria/drug effects , Psychotic Disorders/drug therapy , Thioxanthenes/pharmacology , Animals , Humans , Microbiota
2.
Int Microbiol ; 18(1): 1-12, 2015 Mar.
Article in English | MEDLINE | ID: mdl-26415662

ABSTRACT

Historically, multiplicity of actions in synthetic compounds is a rule rather than exception. The science of non-antibiotics evolved in this background. From the antimalarial and antitrypanosomial dye methylene blue, chemically similar compounds, the phenothiazines, were developed. The phenothiazines were first recognised for their antipsychotic properties, but soon after their antimicrobial functions came to be known and then such compounds were designated as non-antibiotics. The emergence of highly drug-resistant bacteria had initiated an urgent need to search for novel affordable compounds. Several phenothiazines awakened the interest among scientists to determine their antimycobacterial activity. Chlorpromazine, trifluoperazine, methdilazine and thioridazine were found to have distinct antitubercular action. Thioridazine took the lead as researchers repeatedly claimed its potentiality. Although thioridazine is known for its central nervous system and cardiotoxic side-effects, extensive and repeated in vitro and in vivo studies by several research groups revealed that a very small dose of thioridazine is required to kill tubercle bacilli inside macrophages in the lungs, where the bacteria try to remain and multiply silently. Such a small dose is devoid of its adverse side-effects. Recent studies have shown that the (-) thioridazine is a more active antimicrobial agent and devoid of the toxic side effects normally encountered. This review describes the possibilities of bringing down thioridazine and its (-) form to be combined with other antitubercular drugs to treat infections by drug-resistant strains of Mycobacterium tuberculosis and try to eradicate this deadly disease.


Subject(s)
Antitubercular Agents/therapeutic use , Mycobacterium tuberculosis/drug effects , Phenothiazines/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Antipsychotic Agents/therapeutic use , Chlorpromazine/therapeutic use , Humans , Mycobacterium tuberculosis/physiology , Thioridazine/therapeutic use , Trifluoperazine/therapeutic use
3.
Int. microbiol ; 18(1): 1-12, mar. 2015. tab
Article in English | IBECS | ID: ibc-141139

ABSTRACT

Historically, multiplicity of actions in synthetic compounds is a rule rather than exception. The science of non-antibiotics evolved in this background. From the antimalarial and antitrypanosomial dye methylene blue, chemically similar compounds, the phenothiazines, were developed. The phenothiazines were first recognised for their antipsychotic properties, but soon after their antimicrobial functions came to be known and then such compounds were designated as non-antibiotics. The emergence of highly drug-resistant bacteria had initiated an urgent need to search for novel affordable compounds. Several phenothiazines awakened the interest among scientists to determine their antimycobacterial activity. Chlorpromazine, trifluoperazine, methdilazine and thioridazine were found to have distinct antitubercular action. Thioridazine took the lead as researchers repeatedly claimed its potentiality. Although thioridazine is known for its central nervous system and cardiotoxic side-effects, extensive and repeated in vitro and in vivo studies by several research groups revealed that a very small dose of thioridazine is required to kill tubercle bacilli inside macrophages in the lungs, where the bacteria try to remain and multiply silently. Such a small dose is devoid of its adverse side-effects. Recent studies have shown that the (-) thioridazine is a more active antimicrobial agent and devoid of the toxic side effects normally encountered. This review describes the possibilities of bringing down thioridazine and its (-) form to be combined with other antitubercular drugs to treat infections by drug-resistant strains of Mycobacterium tuberculosis and try to eradicate this deadly disease (AU)


No disponible


Subject(s)
Humans , Tuberculosis/drug therapy , Phenothiazines/therapeutic use , Antitubercular Agents/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Mycobacterium tuberculosis/pathogenicity
4.
PLoS One ; 8(3): e57493, 2013.
Article in English | MEDLINE | ID: mdl-23505431

ABSTRACT

A long list of chemotherapeutical drugs used in the treatment of the peripheral and the central nervous systems possess anti-microbial activity. Some of these neurotropic compounds are chiral, with the one stereo isomeric form exaggerating reduced neurotropism. This is the case for the levorotatory form of thioridazine. The phenothiazine thioridazine is an interesting compound, characterized by exhibiting a significant growth inhibiting activity on a wide array of micro-organisms. Thioridazine is characterized by another challenging feature, because the compound is concentrated in certain human tissue cells. The present study describes a comparative study of the two enantiomers as well as the racemic form of thioridazine. The study exploits the stereochemical aspect and the in vitro and in vivo potential of these compounds, with a focus on the effects on gram negative organism Salmonella enterica serover Typhimurium. In summary, the results of this study yielded a significant antibacterial activity of all forms of thioridazine, indicating the levorotatory (-)-form to be superior in terms of both its in vitro and in vivo efficacies.


Subject(s)
Anti-Bacterial Agents/pharmacology , Thioridazine/pharmacology , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/chemistry , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/pathogenicity , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/mortality , Humans , Male , Mice , Microbial Sensitivity Tests , Stereoisomerism , Thioridazine/administration & dosage , Thioridazine/chemistry
5.
Antibiotics (Basel) ; 2(1): 58-72, 2013 Feb 18.
Article in English | MEDLINE | ID: mdl-27029292

ABSTRACT

Phenothiazines have their primary effects on the plasma membranes of prokaryotes and eukaryotes. Among the components of the prokaryotic plasma membrane affected are efflux pumps, their energy sources and energy providing enzymes, such as ATPase, and genes that regulate and code for the permeability aspect of a bacterium. The response of multidrug and extensively drug resistant tuberculosis to phenothiazines shows an alternative therapy for the treatment of these dreaded diseases, which are claiming more and more lives every year throughout the world. Many phenothiazines have shown synergistic activity with several antibiotics thereby lowering the doses of antibiotics administered to patients suffering from specific bacterial infections. Trimeprazine is synergistic with trimethoprim. Flupenthixol (Fp) has been found to be synergistic with penicillin and chlorpromazine (CPZ); in addition, some antibiotics are also synergistic. Along with the antibacterial action described in this review, many phenothiazines possess plasmid curing activities, which render the bacterial carrier of the plasmid sensitive to antibiotics. Thus, simultaneous applications of a phenothiazine like TZ would not only act as an additional antibacterial agent but also would help to eliminate drug resistant plasmid from the infectious bacterial cells.

6.
Indian J Med Res ; 138(4): 541-8, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24434262

ABSTRACT

BACKGROUND & OBJECTIVES: There has been an extensive invasion of tuberculosis at the global level by multidrug resistant as well as extensively drug resistant organisms. Attempts to recover the pathogen in pure culture have frequently failed since the specimens are often highly contaminated and also due to use of insufficient or over-active decontamination procedures. Hence in the present study different methods of decontamination were tested to evaluate their independent efficacies for culture of Mycobacterium tuberculosis. METHODS: A total of 359 samples (241 sputum, 59 urine, 50 endometrium biopsy, 9 pus samples) from clinically suspected cases of tuberculosis were subjected to four different methods of decontamination followed by inoculation in Lowenstein-Jensen medium (LJM), and bilayered medium (BLM) and Kirchner's liquid medium (KLM) to determine the influence of differential decontamination processes. Sputum scanty and positive specimens were graded and each sample was subjected to decontamination by four different techniques. RESULTS: Treatment of specimens with 4 per cent NaOH yielded minimum recovery of pure cultures, while use of 2 per cent NaOH produced higher number of contaminants compared to other methods of decontamination. Addition of N-acetyl L-cystein (NALC) coupled with 2 per cent NaOH to the samples for decontamination provided fairly reasonable recovery, but the highest number of M. tuberculosis cultures could be obtained when the specimens were treated with tri-sodium phosphate and benzalkonium (TSPB). Among the sputum positive cases recovery of growth of M. tuberculosis was higher with greater number of bacilli present in the specimens. Regarding the influence of culture media, BLM produced not only rapid growth, but reasonably higher rate of isolation of M. tuberculosis. INTERPRETATION & CONCLUSIONS: Although use of TSPB was found to be an efficient method of decontamination for successful isolation of M. tuberculosis from contaminated samples, both NALC+ 2 per cent NaOH and TSPB also showed significant recovery of M. tuberculosis cultures in BLM that can facilitate early diagnosis and initiation of treatment.


Subject(s)
Drug Resistance, Multiple, Bacterial , Mycobacterium tuberculosis/drug effects , Sodium Hydroxide/pharmacology , Tuberculosis/microbiology , Benzalkonium Compounds/pharmacology , Decontamination , Endometrium/microbiology , Female , Humans , Mycobacterium tuberculosis/growth & development , Phosphates , Sputum/microbiology , Suppuration/microbiology , Tuberculosis/pathology , Tuberculosis/prevention & control , Urine/microbiology
7.
Indian J Med Res ; 135(6): 913-6, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22825612

ABSTRACT

BACKGROUND & OBJECTIVES: Vibrio cholerae produces acute infection by liberating potent enterotoxin, called cholera toxin in human intestine. Cardiovascular drug lacidipine possessing powerful in vitro action against V. cholerae was tested to determine its possible activity against a toxigenic V. cholerae strain in an established animal model. METHODS: In the rabbit intestine four loops were constructed, 3 of which were injected with over night grown V. cholerae 569B culture. Of these, two loops were simultaneously given graded doses (100, 200 µg) of lacidipine, one was left as such for a positive control. The first loop received sterile medium (negative control). After 18 h, contents of all the loops were examined for accumulation of fluid and number of viable cells. RESULTS: Lacidipine when administrated with live V. cholerae 569B, caused a reduction in the number of viable bacteria along with amount of fluid in the loops. The amount of fluid and number of viable cells were much reduced in the loop that had 200 µg of lacidipine than the loop that received 100 µg of the drug. INTERPRETATION & CONCLUSIONS: Lacidipine has distinct inhibitory action against V. cholerae 569B with respect to both viability and production of cholera toxin in the rabbit ileum. Structural modifications of this compound may possibly lead to procurement of new potent antimicrobial drugs.


Subject(s)
Anti-Infective Agents/administration & dosage , Cholera Toxin/antagonists & inhibitors , Cholera/drug therapy , Dihydropyridines/administration & dosage , Animals , Cardiovascular Agents , Cholera/microbiology , Humans , Intestines/microbiology , Rabbits , Vibrio cholerae/drug effects
8.
Indian J Exp Biol ; 50(7): 491-6, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22822529

ABSTRACT

The antimicrobial efficacy of methylglyoxal (MG) against several gram-negative bacteria including Escherichia coli has been reported. To determine the mechanism of action of MG, molecular interactions between lipid and MG within the liposomal membrane were also investigated. Multilamellar and unilamellar vesicles were prepared from 1, 2-dipalmitoyl-snglycero-3-phosphocholine (DPPC). The effect of MG on DPPC liposomal membrane was studied by fluorescence spectroscopy and differential scanning calorimetry. The results indicate that MG interacts mainly with the DPPC head group that produces a significant increase in the fluidity of liposomal vesicles, which could be the cause of a fusion/aggregation effect in microbial cells. The agarose gel electrophoresis study with the genomic DNA extracted from E. coli ATCC 25922 revealed that addition of MG could completely degrade this DNA within 1 h, pointing out to their distinctly high degree of sensitivity towards MG. Further, the drug was able to cross the cell membranes, penetrating into the interior of the cell and interacting with DNA for demonstrating antibacterial activity of MG.


Subject(s)
Anti-Bacterial Agents/pharmacology , Biomimetics , DNA, Bacterial/metabolism , Membranes, Artificial , Pyruvaldehyde/pharmacology , Calorimetry, Differential Scanning , Electrophoresis, Agar Gel , Escherichia coli/genetics , Spectrometry, Fluorescence
9.
Indian J Exp Biol ; 49(7): 547-51, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21800506

ABSTRACT

The dicarbonyl compound methylglyoxal is a natural constituent of Manuka honey produced from Manuka flowers in New Zealand. It is known to possess both anticancer and antibacterial activity. Such observations prompted to investigate the ability of methylglyoxal as a potent drug against multidrug resistant Pseudomonas aeruginosa. A total of 12 test P. aeruginosa strains isolated from various hospitals were tested for their resistances against many antibiotics, most of which are applied in the treatment of P. aeruginosa infections. Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. Following multiple experimentations it was observed that methylglyoxal was also antimicrobic against all the strains at comparable levels. Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. The fractional inhibitory concentration index of this combination evaluated by checkerboard analysis, was 0.5, which confirmed synergism between the pair. Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial/drug effects , Piperacillin/pharmacology , Pseudomonas aeruginosa/drug effects , Pyruvaldehyde/pharmacology , Anti-Bacterial Agents/administration & dosage , Dose-Response Relationship, Drug , Drug Synergism , Microbial Sensitivity Tests , Piperacillin/administration & dosage , Pyruvaldehyde/administration & dosage
10.
Recent Pat Antiinfect Drug Discov ; 6(2): 128-38, 2011 May.
Article in English | MEDLINE | ID: mdl-21517741

ABSTRACT

Use of the old antipsychotic phenothiazine thioridazine (THZ) for therapy of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) infection is now being seriously considered. It is reported that THZ primarily acts on enzymes involved in fatty acid metabolism and membrane proteins, particularly efflux pumps, as well as oxidoreductases and proteins involved in aerobic respiration that overlap with a number of conventional antituberculous drugs. It targets the products of the Rv3160c-Rv3161c operon, which are perhaps required for the detoxification of THZ, members of the sigma factor SigB regulon that play a crucial role in protecting the pathogen against cell envelope damage, and Rv2745c, a transcription factor that regulates ATP-dependent proteolysis. Some of these genes have been shown to be essential for the survival or persistence of Mycobacterium tuberculosis in the infected host. Since THZ targets multiple pathways, including those involved in cell wall processes and respiratory chain components, it may serve as a model for multi-target drug development, as well as constitute a highly potent addition to a combination of antituberculous drug regimens. The discussion of some of the patents relevant to thioridazine to combat tuberculosis is also included in the present manuscript.


Subject(s)
Antitubercular Agents/therapeutic use , Drug Resistance, Multiple, Bacterial , Extensively Drug-Resistant Tuberculosis/drug therapy , Gene Expression Regulation, Bacterial/drug effects , Mycobacterium tuberculosis/drug effects , Thioridazine/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Animals , Antitubercular Agents/adverse effects , Drug Discovery , Drug Resistance, Multiple, Bacterial/genetics , Drug Therapy, Combination , Extensively Drug-Resistant Tuberculosis/microbiology , Humans , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/pathogenicity , Patents as Topic , Thioridazine/adverse effects , Treatment Outcome , Tuberculosis, Multidrug-Resistant/microbiology
11.
Int J Antimicrob Agents ; 35(2): 174-6, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20005679

ABSTRACT

When administered to mice at doses of 100microg/mouse and 200microg/mouse, thioridazine (TDZ) significantly protected animals from the lethality produced by a virulent strain of Salmonella enterica serovar Typhimurium and reduced the number of bacteria retrieved from the spleen, liver and heart blood. The protection conferred by TDZ against a virulent Salmonella infection is hypothesised to be due to a reduction in the 55kDa virulence protein of the outer membrane of the organism, as this protein is almost totally absent when the organism is exposed to the phenothiazine. It is further hypothesised that the reduction in the 55kDa virulence factor renders the organism susceptible to the action of hydrolytic enzymes of the neutrophil phagolysosome, whereas in the absence of exposure to TDZ intracellular ingestion and localisation of the phagocytosed bacterium does not result in killing owing to rapid induction of the two-step PmrA/B regulon that results in the eventual synthesis and insertion of lipid A into the nascent lipopolysaccharide layer of the outer membrane.


Subject(s)
Anti-Infective Agents/therapeutic use , Antibiotic Prophylaxis/methods , Salmonella Infections, Animal/prevention & control , Salmonella typhimurium/drug effects , Thioridazine/therapeutic use , Animals , Bacterial Proteins/antagonists & inhibitors , Blood/microbiology , Colony Count, Microbial , Liver/microbiology , Male , Mice , Microbial Viability , Neutrophils/microbiology , Spleen/microbiology , Survival Analysis , Virulence Factors/antagonists & inhibitors
13.
Indian J Med Res ; 130(5): 561-6, 2009 Nov.
Article in English | MEDLINE | ID: mdl-20090105

ABSTRACT

BACKGROUND & OBJECTIVE: There is resurgence of tuberculosis in recent years in spite of availability of comprehensive multidrug therapy. Conventional culture media require a long time for the appearance of growth of Mycobacterium tuberculosis, while the other methods are expensive. Hence, a rapid low cost and safe bilayered medium was developed for early growth and sensitivity testing of M. tuberculosis and the results were compared with those on Lowenstein Jensen medium, Middlebrook 7H10 and Kirchner's liquid media. METHODS: A specially designed bilayered medium, consisting of a lower layer of Lowenstein Jensen medium without malachite green and a top layer of Middlebrook 7H 10 medium with added antibiotics and antifungal agents was prepared. Sputum from clinically suspected cases of tuberculosis, pleural fluid and pus samples were inoculated on the bilayered medium along with the inoculation on other conventional media after proper decontamination and concentration of the samples. Antibiotic sensitivity pattern was determined against a few rapidly growing control and test strains by disc diffusion technique and the results could be recorded by 3 to 7 days. RESULTS: Statistically significant (P< 0.001) isolation rate was obtained on this bilayered medium when compared with the other three media, being 81.7 per cent growth by 7 days. Antibiotic sensitivity test could be recorded by 3 days in case of the rapidly growing strains on this medium, and by 7 days in case of M. tuberculosis strains. INTERPRETATION & CONCLUSION: Bilayered medium produced rapid growth earliest by 48 h, higher isolation rates were achieved as compared to the other conventional media and drug sensitivity testing could also be carried out successfully. Thus, the bilayered medium can be used for obtaining early culture report.


Subject(s)
Bacteriological Techniques/methods , Culture Media , Mycobacterium tuberculosis/isolation & purification , Humans , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/growth & development , Tuberculosis/diagnosis , Tuberculosis/microbiology
14.
Eur J Med Chem ; 44(2): 845-53, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18538452

ABSTRACT

A one-pot synthesis of some novel bis-quinolines has been achieved under phase transfer catalyzed conditions using 8-hydroxy quinoline derivatives as substrates. The synthesized analogues were evaluated for antileishmanial activity against Leishmania donovani promastigotes and amastigotes. The entire bis-quinolines showed efficacy in both in vitro and in vivo studies. Compound 5 (1,1-bis-[(5-chloro-8-quinolyl)oxy]methane) exhibited the most significant activity. Compounds 4 (1,1-bis-[(8-quinolyl)oxy]methane) and 9 (1,5-bis-[(2-methyl-8-quinolyl)oxy]pentane) also demonstrated significant leishmanicidal efficacy against established visceral leishmaniasis in BALB/c model. Ultrastructural studies of promastigotes treated with compound 5, demonstrated membrane blebbing, chromatin condensation and vacuolization in the parasites and the flagellated parasites became round shaped after treatment. Moreover, in vitro antibacterial activity of compound 5 against several bacterial strains revealed its promising efficacy. The findings suggested that 1,1-bis-[(5-chloro-8-quinolyl)oxy]methane (5) is a bright candidate to be considered as lead compound for leishmanicidal drug.


Subject(s)
Anti-Bacterial Agents/chemistry , Antiprotozoal Agents/chemistry , Leishmaniasis, Visceral/drug therapy , Quinolines/chemical synthesis , Animals , Catalysis , Leishmania donovani/drug effects , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Parasitic Sensitivity Tests , Quinolines/pharmacology , Structure-Activity Relationship
15.
Int J Antimicrob Agents ; 31(3): 198-208, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18180147

ABSTRACT

Multidrug resistance in Gram-negative bacteria is now known to be primarily caused by overexpression of efflux pumps that extrude unrelated antibiotics from the periplasm or cytoplasm of the bacterium prior to their reaching their intended target. This review focuses on a variety of agents that have been shown to be efflux pump inhibitors (EPIs) and which, if used as 'helper compounds' in combination with antibiotics to which the organism is initially resistant, may produce the required cure. Although not all of the EPIs may serve a helper role owing to their toxicity, they may nevertheless serve as lead compounds.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial/drug effects , Enzyme Inhibitors/pharmacology , Gram-Negative Bacterial Infections/microbiology , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/toxicity , Enzyme Inhibitors/toxicity , Gram-Negative Bacterial Infections/drug therapy , Humans
16.
In Vivo ; 21(5): 847-50, 2007.
Article in English | MEDLINE | ID: mdl-18019422

ABSTRACT

The cardiovascular drug lacidipine was screened in vitro for possible antibacterial activity with respect to 389 Gram-positive and Gram-negative bacterial strains. It was noticed that most bacteria (233) failed to grow at 50-200 microg/mL concentrations of the drug. Some strains were inhibited at even lower concentrations. The bacteria could be arranged according to their decreasing order of sensitivity as follows: Staphylococcus aureus, Vibrio cholerae, Salmonella spp., Shigellae, Escherichia coli, Bacillus spp., Klebsiellae and Pseudomonas spp. Lacidipine was found to be bacteriostatic in nature against S. aureus and V cholerae. When administered to Swiss strain of white mice at doses of 30 and 60 microg/mouse, lacidipine significantly protected the animals challenged with 50 MLD of S. typhimurium NCTC 74. According to the chi-square test, the in vivo data were highly significant (p<0.001).


Subject(s)
Anti-Bacterial Agents/pharmacology , Cardiovascular Agents/pharmacology , Dihydropyridines/pharmacology , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/therapeutic use , Cardiovascular Agents/chemistry , Cardiovascular Agents/therapeutic use , Dihydropyridines/chemistry , Dihydropyridines/therapeutic use , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Male , Mice , Molecular Structure , Salmonella Infections/drug therapy , Salmonella Infections/microbiology , Toxicity Tests
17.
Int J Antimicrob Agents ; 30(3): 242-9, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17644318

ABSTRACT

Diclofenac sodium (Dc), an anti-inflammatory agent, has remarkable inhibitory action both against drug-sensitive and drug-resistant clinical isolates of various Gram-positive and Gram-negative bacteria. The aim of this study was to determine the ability of Dc to protect mice from a virulent Salmonella infection. Dc injected at 1.5 microg/g and 3.0 microg/g mouse body weight significantly protected animals from the lethality of Salmonella infection. As was the case for the in vitro interaction, Dc in combination with streptomycin was even more effective. The non-antibiotic drug Dc has potential for the management of problematic antibiotic-resistant bacterial infections.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Diclofenac/therapeutic use , Drug Resistance, Bacterial , Animals , Anti-Bacterial Agents/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Antipsychotic Agents/pharmacology , Colony Count, Microbial , Culture Media , DNA, Bacterial/genetics , DNA, Bacterial/isolation & purification , Diclofenac/toxicity , Drug Synergism , Escherichia coli/drug effects , Escherichia coli Infections/drug therapy , Escherichia coli Infections/microbiology , Male , Mice , Microbial Sensitivity Tests , Plasmids/genetics , Salmonella enterica/drug effects , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcus aureus/drug effects , Streptomycin/pharmacology , Trifluoperazine/pharmacology
18.
Int J Antimicrob Agents ; 30(4): 336-40, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17644321

ABSTRACT

The non-steroidal anti-inflammatory drug diclofenac (DCL) shows noteworthy in vitro and in vivo antimycobacterial activity. The aim of this study was to ascertain whether DCL used in combination with the first-line antitubercular antibiotic streptomycin (STM) synergistically augments its efficacy in vitro as well as in a murine tuberculosis infection model. In vitro minimum inhibitory concentrations (MICs) and synergistic activities of the drugs with respect to standard strains and clinical isolates of Mycobacterium tuberculosis were determined. Swiss albino male mice were intravenously infected with 2.3x10(7) M. tuberculosis H37Rv. Mice were treated with DCL or STM alone as well as in combination for 4 weeks to determine the survival rate, spleen weight and colony-forming unit (CFU) counts in the lungs and spleen. DCL was bactericidal at 40 microg/mL (4xMIC) against M. tuberculosis H37Rv and was synergistic with STM in vitro (fractional inhibitory concentration index 0.37). A dose of 10 microg/g/day DCL or 150 microg/g/day STM for 4 weeks, administered from 1 day post infection, significantly (P<0.05) lowered bacterial counts and reduced mean spleen weight of mice compared with untreated animals. Simultaneous administration of both agents further decreased CFU counts (P<0.05) in the lungs and spleen compared with mice receiving STM alone. Thus, the ability of extended antibiotic therapy may be improved with the help of this synergistic drug pair in murine tuberculosis, and further investigations may throw light on new directions to combat multidrug-resistant tuberculosis infections in humans.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Diclofenac/therapeutic use , Mycobacterium tuberculosis/drug effects , Streptomycin/therapeutic use , Tuberculosis/drug therapy , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Diclofenac/administration & dosage , Diclofenac/pharmacology , Disease Models, Animal , Drug Synergism , Drug Therapy, Combination , Lung/microbiology , Male , Mice , Microbial Sensitivity Tests , Microbial Viability , Spleen/microbiology , Spleen/pathology , Streptomycin/administration & dosage , Streptomycin/pharmacology , Survival Analysis
19.
In Vivo ; 20(5): 613-9, 2006.
Article in English | MEDLINE | ID: mdl-17091768

ABSTRACT

E. coli is the main agent of uncomplicated urinary tract infections (UTIs) and accounts for more than 85% of recurrent cystitis and at least 35% of recurrent pyelonephritis. Despite the widespread availability of antibiotics, UTIs remain the most common bacterial infection in the human population. It is currently advised that the clinical administration of antibiotics against the pathogenic bacteria should be prohibitted due to the emergence of multidrug resistant (MDR) bacterial strains. Therefore, newer and more effective antimicrobials are in demand to treat such cases. One hundred and thirty six urine samples were collected from UTI patients. E. coli was isolated from 85 samples, out of which 33% were resistant to common antibiotics. The isolates were decreasingly resistant to ampicillin, tobramycin, augmentin, nalidixic acid, cefuroxime, nitrofurantoin, kanamycin, pipemidic acid, chloramphenicol, cefotaxime, cefamendol, ofloxacin, ceftizoxime, norfloxacin and amikacin. The anti-inflammatory drug diclofenac exhibited significant antibacterial activity against common bacterial strains both in vitro and in vivo. The present work was conducted to evaluate the in vitro inhibitory effect of this drug on the clinically isolated strains of E. coli in hospitals. All the isolates were sensitive to diclofenac, with MIC values ranging from 5-50 microg/mL. The MIC90 value of the drug was 25 microg/mL. Therefore, it may be suggested that diclofenac has the capacity to treat UTI caused by E. coli.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cyclooxygenase Inhibitors/therapeutic use , Diclofenac/therapeutic use , Escherichia coli Infections/therapy , Urinary Tract Infections/drug therapy , Animals , Cyclooxygenase Inhibitors/pharmacokinetics , Diclofenac/chemistry , Diclofenac/pharmacokinetics , Drug Resistance, Bacterial , Escherichia coli/genetics , Escherichia coli Infections/urine , Humans , Male , Mice , Microbial Sensitivity Tests , Molecular Structure
20.
In Vivo ; 20(1): 97-102, 2006.
Article in English | MEDLINE | ID: mdl-16433035

ABSTRACT

Thepiperazine chlorcyclizine HCl (CCZ), possessing significant antimetabolic as well as virucidal and virustatic activities against the human immunodeficiency virus (HIV) and other retroviruses, was selected to determine its anticarcinogenic potential The anticancer activity of CCZ was evaluated against procarcinogen n-diethylnitrosamine (NDA)-initiated hepatocarcinogenesis, which was subsequently promoted by phenobarbital (PB) in male Sprague-Dawley rats. The anticancer efficacy of CCZ was monitored by estimating some potential markers of neoplastic and preneoplastic hepatic conditions, e.g., glutathione (GSH), glutathione-S-transferase (GST) and gamma-glutamyl transpeptidase (gammaGTP). CCZ exhibited antineoplastic activity on a long-term therapeutic basis. Furthermore, this drug restricted the exponential increase of the antioxidant markers in the hyperplastic nodule and the surrounding liver tissues in comparison with the carcinogen-controlled rats during the entire period of treatment. A decrease in the number of nodules was observed in the CCZ-treated group.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms, Experimental/drug therapy , Piperazines/therapeutic use , Animals , Carcinogens/toxicity , Carcinoma, Hepatocellular/chemically induced , Carcinoma, Hepatocellular/pathology , Diethylnitrosamine/toxicity , Liver Neoplasms, Experimental/chemically induced , Liver Neoplasms, Experimental/pathology , Male , Phenobarbital/toxicity , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...